Skip to main content

Jose Ramon Conejo-Garcia

Professor in Integrative Immunobiology
Integrative Immunobiology
2128 MSRBIII, 3 Genome Ct, Durham, NC 27710

Overview


Jose Conejo-Garcia’s research program focuses on understanding and targeting the mechanisms governing the balance between immunosuppression and protective immunity in the tumor microenvironment, with an emphasis on the crosstalk between innate (gamma/delta) and adaptive (alpha/beta) T cells, and B lymphocytes, including in Tertiary Lymphoid Structures. Discoveries for the Conejo-Garcia lab are also being translated in active clinical trials using CAR T cells to treat ovarian cancer patients. 

Current Appointments & Affiliations


Professor in Integrative Immunobiology · 2024 - Present Integrative Immunobiology, Basic Science Departments
Member of the Duke Cancer Institute · 2023 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published June 26, 2025
Fighting Cancer With Better Immunotherapy
Published February 3, 2025
Celebrating Duke’s New Full Professors
Published November 1, 2023
Antibody Targets Cancer Mutations Once Considered Untreatable

View All News

Recent Publications


Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 26, 2025 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 26, 2025 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 26, 2025 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite
View All Publications

Recent Grants


Novel immunotherapies using optimized tumor cell-penetrating antibodies

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2025 - 2029

McCain/Bayh Glioblastoma Consortium

Clinical TrialCo Investigator · Awarded by Department of Defense · 2025 - 2029

Crosstalk between butyrophilins and gamma delta T cells in human cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2024 - 2029

View All Grants

Education, Training & Certifications


University of Alcalá (Spain) · 1998 MD./PhD.